Amphotericin B lipid complex for neonatal invasive candidiasis
- aMiller Children's Hospital, Long Beach, California and University of California, Irvine, California, USA, bThe Liposome Company, Princeton, New Jersey, USA
- Dr Lieberman, Pediatric Infectious Diseases, Miller Children's Hospital, 2801 Atlantic Ave, PO Box 1428, Long Beach, CA 90801–1428, USAjmlieberman{at}pol.net
- Accepted 26 September 2000
Abstract
This study describes the safety and efficacy of amphotericin B lipid complex (ABLC) in 11 neonates with systemicCandida infections. Nine of the 11 improved clinically, and eight of nine evaluable patients had a mycological cure with ABLC. Creatinine levels improved or did not significantly change in eight of the 11 patients.
